Skip to content

G&A at other companies

CTO
Citius Oncology, Inc.CTOR
$23.63M+953%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$4.12M+4.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$7.22M+45.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$37.59M-8.4%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.69M-9.7%

Segments

By product

See full
Employee Related Expenses$859K-9.3%
Professional Fees For Services$790K-30.6%
Facilities And Other Expenses$508K+8.1%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's G&A?
RNTX (RNTX) reported G&A of $2.16M in Q1 2026.
How has RNTX's G&A changed year-over-year?
RNTX's G&A decreased by 15.6% year-over-year, from $2.56M to $2.16M.
What is the long-term trend for RNTX's G&A?
Over 4 years (2021 to 2025), RNTX's G&A has grown at a 3.2% compound annual growth rate (CAGR), from $9.6M to $10.9M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.